Docstoc

Aarkstore Von Willebrand Disease – Pipeline Review, H1 2012

Document Sample
Aarkstore Von Willebrand Disease – Pipeline Review, H1 2012 Powered By Docstoc
					Von Willebrand Disease – Pipeline Review, H1 2012

Summary

Global Markets Direct, Von Willebrand Disease Pipeline Review, H1 2012, provides an
overview of the Von Willebrand Disease therapeutic pipeline. This report provides information
on the therapeutic development for Von Willebrand Disease, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players involved in
the therapeutic development for Von Willebrand Disease. Von Willebrand Disease Pipeline
Review, H1 2012 is built using data and information sourced from Global Markets Direct
proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources,
put together by Global Markets Direct team.

Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.

Scope

A snapshot of the global therapeutic scenario for Von Willebrand Disease.
A review of the Von Willebrand Disease products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources.
Coverage of products based on various stages of development ranging from discovery till
registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Von Willebrand Disease pipeline on the basis of route of administration and
molecule type.
Profiles of late-stage pipeline products featuring sections on product description, mechanism of
action and research & development progress.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Von
Willebrand Disease.
Identify emerging players with potentially strong product portfolio and design effective counter-
strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players with the most promising
pipeline.
Devise corrective measures for pipeline projects by understanding Von Willebrand Disease
pipeline depth and focus of Von Willebrand Disease therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline.

For more information, please visit :-

http://www.aarkstore.com/reports/Von-Willebrand-Disease-Pipeline-Review-H1-2012-
194397.html

Marketing Team

Aarkstore Enterprise

Phone:08149852585

Email:enquiry@aarkstore.com

URL:www.aarkstore.com

http://twitter.com/aarkstoredotcom

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstoreenterprise

More Related Reports :-

Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012
Restless Legs Syndrome – Pipeline Review, H1 2012
Hyperoxaluria – Pipeline Review, H1 2012
Candidiasis – Pipeline Review, H1 2012
Neutropenia – Pipeline Review, H1 2012
Brain Hemorrhage – Pipeline Review, H1 2012
H1N1 Infection – Pipeline Review, H1 2012
Von Willebrand Disease – Pipeline Review, H1 2012
Dystonia – Pipeline Review, H1 2012
Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2012

				
DOCUMENT INFO
Description: Aarkstore announce a new report " Von Willebrand Disease – Pipeline Review, H1 2012" through its vast collection of market research report